Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115,

Post time 3 day(s) ago

Edited by Torimochi2 at 2024-7-5 14:48

journal：European Journal of Cancer

Authors：Caroline Robert; Brian Gastman; Helen Gogas; Piotr Rutkowski; Georgina V. Long; Marya F. Chaney; Harshada Joshi; Yu-Lin Lin; Wendy Snyder; Jason A. Chesney

Published date：2024-8-

DOI：10.1016/j.ejca.2024.114120

PDF link：https://www.sciencedirect.com/sc ... 959804924007767/pdf

Article link：http://dx.doi.org/10.1016/j.ejca.2024.114120

Article Source：Elsevier BV。

Remark：

Post time 3 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Elsevier] Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115,

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Elsevier] Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115, Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Elsevier] Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115,